

October 28, 2025

Q2FY26 Result Update

☑ Change in Estimates | ☑ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	HOLD		HOLD	
Target Price	3,123		3,016	
Sales (Rs. m)	1,77,733	1,96,650	1,77,733	1,96,650
% Chng.	-	-	-	-
EBITDA (Rs. m)	37,646	43,454	37,204	43,865
% Chng.	1.2	(0.9)	-	-
EPS (Rs.)	64.2	76.7	63.5	77.3
% Chng.	1.0	(0.8)	-	-

Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	1,46,931	1,61,870	1,77,733	1,96,650
EBITDA (Rs. m)	27,184	33,902	37,646	43,454
Margin (%)	18.5	20.9	21.2	22.1
PAT (Rs. m)	12,508	17,275	19,089	22,799
EPS (Rs.)	42.1	58.1	64.2	76.7
Gr. (%)	(6.4)	38.1	10.5	19.4
DPS (Rs.)	5.0	7.0	7.7	9.2
Yield (%)	0.2	0.2	0.3	0.3
RoE (%)	10.4	12.9	12.7	13.6
RoCE (%)	11.6	13.6	13.5	14.4
EV/Sales (x)	6.4	5.8	5.3	4.7
EV/EBITDA (x)	34.4	27.6	24.8	21.4
PE (x)	72.0	52.1	47.2	39.5
P/BV (x)	7.1	6.4	5.7	5.1

Key Data

SRFL.BO | SRF IN

52-W High / Low	Rs.3,325 / Rs.2,127
Sensex / Nifty	84,628 / 25,936
Market Cap	Rs.897bn / \$ 10,168m
Shares Outstanding	296m
3M Avg. Daily Value	Rs.1147.03m

Shareholding Pattern (%)

Promoter's	50.26
Foreign	17.98
Domestic Institution	19.53
Public & Others	12.91
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	7.9	(0.4)	34.1
Relative	2.5	(5.6)	26.8

Swarnendu Bhushan

swarnendubhushan@plindia.com | 91-22-66322260

Saurabh Ahire

saurabhahire@plindia.com | 91-22-66322537

Tejas Kadam

tejaskadam@plindia.com | 91-22-66322222

Ref gas drives growth amid Agro weakness

Quick Pointers:

- Launched one new AI, three agro products and three pharma products in H1FY26
- Capex for Chemours link fluoropolymers project raised from Rs5.95bn to Rs7.45bn.

SRF reported consolidated revenue of Rs36.4bn, registering a 6.3% YoY increase but a 4.7% sequential decline. The Chemicals segment remained the key growth driver, posting a robust 23% YoY rise; however, it declined by 9% QoQ due to deferred sales by major agrochemical customers. The Fluorochemicals business delivered strong growth, supported by higher volumes and improved realizations. The Performance Films segment declined 1% YoY and QoQ, with margins contracting by 150bps sequentially, impacted by an influx of low-cost imports from China and temporary disruptions linked to GST 2.0. The Technical Textiles business also came under pressure from cheap imports and US tariff-related challenges.

Rising refrigerant prices, particularly for R32, driven by the ongoing consumer trade-in program in China, have supported near-term performance. However, we do not expect this program to continue, which could lead to a moderation in R32 prices going forward. Additionally, subdued agrochemical demand and persistent oversupply from Chinese producers remain key concerns. We remain cautious on the stock maintaining 'HOLD' rating on stock with a SOTP-based target price of Rs3,123.

- Chemicals business grew 23%YoY:** Consolidated revenue increases 6.3% YoY but declined 4.7% QoQ to Rs36.4bn (PLe: Rs40.4bn; Consensus: Rs38.4bn), driven by a 23% YoY increase in the Chemicals segment, with EBIT margins expanding 1080bps YoY. However, the technical textile segment reported a 41% YoY decline in revenue, alongside a 440bps YoY contraction in EBIT margin. H1FY26 revenue increased by 8.3%, driven by 23% growth in the Chemicals segment, Technical Textile business remained subdued in H1FY26.
- Chemical segment margins expand sharply YoY:** Gross margin stood at 51.4%, increased from 46.4% in Q2FY25 and 50% in Q1FY26, due to slight decrease in raw material prices. EBITDA stood at Rs8bn (PLe: Rs8.9bn, Consensus: Rs8.2bn; 43.9% YoY, -6.7% QoQ). EBITDAM increased to 22.1% vs. 16.4% in Q2FY25 but decreased sequentially by 60bps. H1FY26 EBITDA increased by 37.6% vs H1FY25, led by margin expansion in the Chemicals business. EBIT in chemicals segment was down 4% QoQ but increased 96% YoY, however EBIT Margin for the segment increased by 1080bps YoY to 28.9%.
- Key concall takeaways: (1)** FY26 capex is expected to be around Rs22-23bn. **(2)** In the Specialty Chemicals segment recently launched products showed strong traction. **(3)** The company launched one new active Ingredient (AI), three new Agro and one new Pharma product during H1FY26. **(4)** New land

purchased in Odisha for setting up new chemical facility. **(5)** Specialty Chemical Domestic: Exports mix – 43%: 66%. **(6)** With the agreement with Chemours in place, capex for the fluoropolymers project has been revised upward from Rs5.95bn to Rs7.45bn. The project will be executed in phases and is expected to be completed by Dec’ 26. **(7)** H2FY26 is expected to have better steady pricing for Ref gas. **(8)** Fluorochemicals Domestic: Exports mix – 40%:60%. **(9)** GST reforms led to short-term volume impact on Performance film business. **(10)** China dumping continue to impact Belting Fabric and Nylon cord segment.

Exhibit 1: Valuation – SOTP-based TP at Rs3,123; maintain ‘Hold’ rating

	Avg EBITDA (Rs mn) FY27E/FY28E	Target EV/EBITDA multiple	Total Enterprise Value (Rs mn)
Specialty Chemicals	32,258	26	8,38,710
Packaging Films Business	8,151	11	89,658
Technical Textiles Business	2,701	11	29,710
Total Enterprise Value	43,110		9,58,079
less: Net Debt (FY26/FY27)			33,783
Total			9,24,296
No of shares			296
TP			3,123

Source: PL

Exhibit 2: Q2FY26 Result Overview – Consolidated (Rs mn)

Y/e March	Q2FY26	Q2FY25	YoY gr. (%)	Q2FY26E	% Var.	Q1FY26	QoQ gr. (%)	H1FY26	H1FY25	YoY gr. (%)
Net Sales	36,402	34,243	6.3	40,467	(10.0)	38,186	(4.7)	74,588	68,884	8.3
Gross Profit	18,712	15,903	17.7	20,293	(7.8)	19,079	(1.9)	37,791	32,273	17.1
Margin (%)	51.4	46.4		50.1		50.0		50.7	46.9	
EBITDA	8,048	5,606	43.5	8,870	(9.3)	8,212	(2.0)	16,259	11,813	37.6
Margin (%)	22.1	16.4		21.9		21.5		21.8	17.1	
Other Income	257	333	(22.9)	332	(22.5)	291	(11.7)	548	586	(6.4)
Depreciation	2,121	1,939	9.4	2,091	1.5	2,032	4.4	4,154	3,821	8.7
EBIT	5,877	4,000	46.9	7,111	(17.3)	6,470	(9.2)	12,435	8,180	52.0
Interest	707	938	(24.6)	865	(18.3)	799	(11.5)	1,506	1,903	(20.9)
PBT before exceptional items	5,171	3,063	68.8	6,246	(17.2)	5,671	(8.8)	10,929	6,277	74.1
Total Tax	1,289	822	56.7	1,533	(15.9)	1,435	(10.2)	2,724	1,740	56.5
ETR (%)	25	27		25	1.6	25	(1.5)	25	28	(10.1)
Adj. PAT	3,882	2,240	73.3	4,713	(17.6)	4,236	(8.4)	8,205	4,537	80.9
PAT	3,882	2,240	73.3	4,713	(17.6)	4,236	(8.4)	8,205	4,537	80.9


Source: Company, PL

Exhibit 3: Segmental Details (Rs mn)

	Q4FY25	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26
Revenue from Operations	35,734	34,698	34,267	34,913	43,133	38,186	36,402
Chemicals Business (CB)	18,161	14,820	13,578	14,957	23,553	18,390	16,669
Packing Film Business (PFB)	11,824	13,363	14,206	13,848	14,122	14,182	14,081
Technical Textile Business (TTB)	4,689	5,253	5,355	5,098	4,584	4,666	4,743
Others	1,062	1,262	1,128	1,011	874	949	908
Less : Inter Segment Revenues	37	56	24	0			
Total Segment Revenue	35,697	34,641	34,243	34,913	43,133	38,186	36,402
Add : Other Unallocable Income							
Net Revenue from Operations	35,697	34,641	34,243	34,913	43,133	38,186	36,402
Change (YoY %)	-6%	4%	8%	14%	21%	10%	6%
Chemicals Business (CB)	-14%	-11%	-5%	7%	30%	24%	23%
Packing Film Business (PFB)	3%	22%	27%	27%	19%	6%	-1%
Technical Textile Business (TTB)	9%	13%	6%	11%	-2%	-11%	-11%
Others	13%	6%	-11%	-11%	-18%	-25%	-19%
Change (QoQ %)	17%	-3%	-1%	2%	24%	-11%	-5%
Chemicals Business (CB)	30%	-18%	-8%	10%	57%	-22%	-9%
Packing Film Business (PFB)	8%	13%	6%	-3%	2%	0%	-1%
Technical Textile Business (TTB)	2%	12%	2%	-5%	-10%	2%	2%
Others	-7%	19%	-11%	-10%	-14%	9%	-4%
Revenue Mix (%)	51%	43%	40%	43%	55%	48%	46%
Chemicals Business (CB)	33%	39%	41%	40%	33%	37%	39%
Packing Film Business (PFB)	13%	15%	16%	15%	11%	12%	13%
Technical Textile Business (TTB)	3%	4%	3%	3%	2%	2%	2%
Others	51%	43%	40%	43%	55%	48%	46%
Profit/Loss Before Interest and Tax	6,161	4,844	4,175	5,287	9,056	6,942	6,501
Chemicals Business (CB)	4,977	3,064	2,461	3,638	7,485	5029.2	4,813
Packing Film Business (PFB)	331	868	828	904	1,046	1402	1,190
Technical Textile Business (TTB)	698	677	713	589	401	376.4	423
Others	156	236	172	157	124	134.3	75
Less: Other Un-allocable Expenditure	828	439	400	637	1,089	385	623
Unallocated Exp as % of Rev	2.3%	1.3%	1.2%	1.8%	2.5%	1.0%	1.7%
EBIT (incl Other Income)	5,333	4,405	3,774	4,650	7,968	6,557	5,877
Less: Other Income	234	253	333	396	345	291	257
EBIT	5,099	4,153	3,441	4,253	7,623	6,266	5,620
Less: Finance Costs	900	965	938	963	894	799	707
PBT	4,433	3,440	2,837	3,687	7,074	5,758	5,171


Source: Company, PL

Exhibit 4: Chemicals contribution to be at 54% in FY28E




Source: Company, PL

Exhibit 5: EBITDA margin to improve with high value add mix




Source: Company, PL

Exhibit 6: PAT margins to improve to ~12% in FY28E



Source: Company, PL

Exhibit 7: Revenue to grow at 10% CAGR over FY25-28E



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	1,46,931	1,61,870	1,77,733	1,96,650
YoY gr. (%)	11.8	10.2	9.8	10.6
Cost of Goods Sold	76,992	81,166	88,442	96,161
Gross Profit	69,939	80,703	89,290	1,00,489
Margin (%)	47.6	49.9	50.2	51.1
Employee Cost	10,425	11,485	12,610	13,952
Other Expenses	32,330	35,316	39,035	43,083
EBITDA	27,184	33,902	37,646	43,454
YoY gr. (%)	5.2	24.7	11.0	15.4
Margin (%)	18.5	20.9	21.2	22.1
Depreciation and Amortization	7,715	8,554	9,407	10,397
EBIT	19,469	25,348	28,239	33,057
Margin (%)	13.3	15.7	15.9	16.8
Net Interest	3,760	3,642	4,141	4,282
Other Income	1,327	1,327	1,354	1,421
Profit Before Tax	17,037	23,034	25,451	30,197
Margin (%)	11.6	14.2	14.3	15.4
Total Tax	4,529	5,758	6,363	7,398
Effective tax rate (%)	26.6	25.0	25.0	24.5
Profit after tax	12,508	17,275	19,089	22,799
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	12,508	17,275	19,089	22,799
YoY gr. (%)	(6.4)	38.1	10.5	19.4
Margin (%)	8.5	10.7	10.7	11.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	12,508	17,275	19,089	22,799
YoY gr. (%)	(6.4)	38.1	10.5	19.4
Margin (%)	8.5	10.7	10.7	11.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	12,508	17,275	19,089	22,799
Equity Shares O/s (m)	297	297	297	297
EPS (Rs)	42.1	58.1	64.2	76.7

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	1,82,137	1,98,034	2,20,034	2,42,034
Tangibles	1,76,926	1,92,823	2,14,823	2,36,823
Intangibles	5,211	5,211	5,211	5,211
Acc: Dep / Amortization	44,939	53,493	62,899	73,296
Tangibles	43,747	52,301	61,708	72,104
Intangibles	1,191	1,191	1,191	1,191
Net fixed assets	1,37,198	1,44,541	1,57,135	1,68,738
Tangibles	1,33,179	1,40,522	1,53,115	1,64,719
Intangibles	4,019	4,019	4,019	4,019
Capital Work In Progress	8,110	14,213	14,213	14,213
Goodwill	-	-	-	-
Non-Current Investments	5,773	3,919	3,919	3,919
Net Deferred tax assets	(10,196)	(10,196)	(10,196)	(10,196)
Other Non-Current Assets	2,838	2,838	2,838	2,838
Current Assets				
Investments	7,045	7,045	7,045	7,045
Inventories	23,490	25,878	28,414	31,438
Trade receivables	21,695	23,900	26,243	29,036
Cash & Bank Balance	3,538	15,977	20,690	27,105
Other Current Assets	1,681	1,852	2,034	2,250
Total Assets	2,15,571	2,44,759	2,67,540	2,92,088
Equity				
Equity Share Capital	2,974	2,964	2,964	2,964
Other Equity	1,23,288	1,38,441	1,55,189	1,75,203
Total Networth	1,26,262	1,41,405	1,58,154	1,78,167
Non-Current Liabilities				
Long Term borrowings	26,599	26,599	26,599	23,939
Provisions	826	826	826	826
Other non current liabilities	3,818	3,818	3,818	3,818
Current Liabilities				
ST Debt / Current of LT Debt	19,813	31,042	34,084	37,711
Trade payables	23,316	25,686	28,204	31,206
Other current liabilities	4,384	4,830	5,303	5,868
Total Equity & Liabilities	2,15,571	2,44,759	2,67,540	2,92,088

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	17,037	23,034	25,451	30,197
Add. Depreciation	7,715	8,554	9,407	10,397
Add. Interest	3,760	3,642	4,141	4,282
Less Financial Other Income	1,327	1,327	1,354	1,421
Add. Other	(121)	(1,327)	(1,354)	(1,421)
Op. profit before WC changes	28,390	33,902	37,646	43,454
Net Changes-WC	(176)	(2,367)	(2,513)	(2,997)
Direct tax	(3,339)	(5,731)	(6,334)	(7,364)
Net cash from Op. activities	24,875	25,804	28,798	33,093
Capital expenditures	(12,223)	(22,000)	(22,000)	(22,000)
Interest / Dividend Income	355	1,327	1,354	1,421
Others	(2,972)	1,854	-	-
Net Cash from Invst. activities	(14,840)	(18,819)	(20,646)	(20,579)
Issue of share cap. / premium	-	(10)	-	-
Debt changes	(4,291)	11,228	3,042	968
Dividend paid	(2,132)	(2,073)	(2,291)	(2,736)
Interest paid	(3,931)	(3,642)	(4,141)	(4,282)
Others	(335)	(49)	(49)	(49)
Net cash from Fin. activities	(10,689)	5,454	(3,439)	(6,099)
Net change in cash	(653)	12,439	4,713	6,415
Free Cash Flow	12,560	3,804	6,798	11,093

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	42.1	58.1	64.2	76.7
CEPS	68.0	86.8	95.8	111.6
BVPS	424.5	475.4	531.7	599.0
FCF	42.2	12.8	22.9	37.3
DPS	5.0	7.0	7.7	9.2
Return Ratio(%)				
RoCE	11.6	13.6	13.5	14.4
ROIC	9.0	11.2	11.5	12.6
RoE	10.4	12.9	12.7	13.6
Balance Sheet				
Net Debt : Equity (x)	0.3	0.2	0.2	0.2
Net Working Capital (Days)	54	54	54	54
Valuation(x)				
PER	72.0	52.1	47.2	39.5
P/B	7.1	6.4	5.7	5.1
P/CEPS	44.5	34.9	31.6	27.1
EV/EBITDA	34.4	27.6	24.8	21.4
EV/Sales	6.4	5.8	5.3	4.7
Dividend Yield (%)	0.2	0.2	0.3	0.3

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q3FY25	Q4FY25	Q1FY26	Q2FY26
Net Revenue	34,913	43,133	38,186	36,402
YoY gr. (%)	14.4	20.8	10.2	6.3
Raw Material Expenses	18,056	22,324	19,107	17,690
Gross Profit	16,857	20,809	19,079	18,712
Margin (%)	48.3	48.2	50.0	51.4
EBITDA	6,196	9,574	8,298	7,742
YoY gr. (%)	9.5	37.6	37.5	43.9
Margin (%)	17.7	22.2	21.7	21.3
Depreciation / Depletion	1,943	1,952	2,032	2,121
EBIT	4,253	7,623	6,266	5,620
Margin (%)	12.2	17.7	16.4	15.4
Net Interest	963	894	799	707
Other Income	396	345	291	257
Profit before Tax	3,687	7,074	5,758	5,171
Margin (%)	10.6	16.4	15.1	14.2
Total Tax	968	1,813	1,435	1,289
Effective tax rate (%)	26.3	25.6	24.9	24.9
Profit after Tax	2,719	5,261	4,323	3,882
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	2,719	5,261	4,323	3,882
YoY gr. (%)	7.3	24.6	71.4	92.7
Margin (%)	7.8	12.2	11.3	10.7
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	2,719	5,261	4,323	3,882
YoY gr. (%)	7.3	24.6	71.4	92.7
Margin (%)	7.8	12.2	11.3	10.7
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	2,719	5,261	4,323	3,882
Avg. Shares O/s (m)	296	296	296	296
EPS (Rs)	9.2	17.8	14.6	13.1

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	07-Oct-25	Hold	2,894	2,943
2	29-Sep-25	Hold	2,947	2,807
3	24-Jul-25	Hold	3,071	3,150
4	07-Jul-25	Hold	3,069	3,231
5	14-May-25	Hold	3,069	2,928
6	08-Apr-25	Hold	2,780	2,721
7	27-Feb-25	Hold	2,820	2,768
8	30-Jan-25	Hold	2,698	2,831
9	08-Jan-25	Reduce	2,018	2,308

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Hold	395	377
2	Bharat Petroleum Corporation	Hold	347	342
3	Bharti Airtel	Accumulate	2,090	1,930
4	Clean Science and Technology	Hold	1,111	1,068
5	Deepak Nitrite	Hold	1,924	1,844
6	Fine Organic Industries	BUY	5,571	4,651
7	GAIL (India)	Accumulate	199	177
8	Gujarat Fluorochemicals	Hold	3,742	3,643
9	Gujarat Gas	Hold	442	436
10	Gujarat State Petronet	Accumulate	339	325
11	Hindustan Petroleum Corporation	Accumulate	458	446
12	Indian Oil Corporation	Accumulate	162	150
13	Indraprastha Gas	Reduce	192	209
14	Jubilant Ingrevia	Hold	695	677
15	Laxmi Organic Industries	Reduce	199	215
16	Mahanagar Gas	BUY	1,471	1,281
17	Mangalore Refinery & Petrochemicals	Accumulate	159	142
18	Navin Fluorine International	Accumulate	5,196	4,568
19	NOCIL	Hold	187	181
20	Oil & Natural Gas Corporation	BUY	278	244
21	Oil India	BUY	525	415
22	Petronet LNG	Hold	290	279
23	Reliance Industries	BUY	1,668	1,417
24	SRF	Hold	2,894	2,943
25	Vinati Organics	BUY	1,946	1,690

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan- IIT, MBA Finance, Mr. Saurabh Ahire- MBA, Passed CFA Level II, Mr. Tejas Kadam- BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com